Home Cart 0 Sign in  
X

[ CAS No. 1127-45-3 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
3d Animation Molecule Structure of 1127-45-3
Chemical Structure| 1127-45-3
Chemical Structure| 1127-45-3
Structure of 1127-45-3 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 1127-45-3 ]

Related Doc. of [ 1127-45-3 ]

Alternatived Products of [ 1127-45-3 ]

Product Details of [ 1127-45-3 ]

CAS No. :1127-45-3 MDL No. :MFCD00006739
Formula : C9H7NO2 Boiling Point : -
Linear Structure Formula :- InChI Key :FJKUOCCQEBLPNX-UHFFFAOYSA-N
M.W : 161.16 Pubchem ID :14312
Synonyms :

Calculated chemistry of [ 1127-45-3 ]

Physicochemical Properties

Num. heavy atoms : 12
Num. arom. heavy atoms : 10
Fraction Csp3 : 0.0
Num. rotatable bonds : 0
Num. H-bond acceptors : 2.0
Num. H-bond donors : 1.0
Molar Refractivity : 47.13
TPSA : 45.69 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : Yes
P-gp substrate : No
CYP1A2 inhibitor : Yes
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -6.99 cm/s

Lipophilicity

Log Po/w (iLOGP) : 1.44
Log Po/w (XLOGP3) : 0.41
Log Po/w (WLOGP) : 1.18
Log Po/w (MLOGP) : 1.39
Log Po/w (SILICOS-IT) : 0.66
Consensus Log Po/w : 1.02

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 1.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -1.71
Solubility : 3.11 mg/ml ; 0.0193 mol/l
Class : Very soluble
Log S (Ali) : -0.94
Solubility : 18.7 mg/ml ; 0.116 mol/l
Class : Very soluble
Log S (SILICOS-IT) : -1.72
Solubility : 3.08 mg/ml ; 0.0191 mol/l
Class : Soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 2.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 1.66

Safety of [ 1127-45-3 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P261-P305+P351+P338 UN#:N/A
Hazard Statements:H302-H315-H319 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 1127-45-3 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 1127-45-3 ]
  • Downstream synthetic route of [ 1127-45-3 ]

[ 1127-45-3 ] Synthesis Path-Upstream   1~13

  • 1
  • [ 1127-45-3 ]
  • [ 70125-16-5 ]
Reference: [1] Journal of Chemical Sciences, 2010, vol. 122, # 6, p. 847 - 855
[2] Organic Process Research and Development, 2004, vol. 8, # 4, p. 663 - 665
[3] Bioorganic and Medicinal Chemistry, 2016, vol. 24, # 19, p. 4741 - 4749
  • 2
  • [ 1127-45-3 ]
  • [ 15450-76-7 ]
Reference: [1] Canadian Journal of Chemistry, 2005, vol. 83, # 5, p. 460 - 470
[2] Journal of Fluorescence, 2018, vol. 28, # 5, p. 1121 - 1126
  • 3
  • [ 148-24-3 ]
  • [ 1127-45-3 ]
YieldReaction ConditionsOperation in experiment
97% With manganese dioxide; dihydrogen peroxide In dichloromethane (1)
8-Hydroxyquinoline N-oxide
59.74 g (411 mmol) of 8-hydroxyquinoline, 350 ml (822 mmol) of dichloromethane, 82.2 ml of 35percent aqueous hydrogen peroxide solution and 0.52 g (2.5 mmol) of methylrhenium trioxide (MTO) are placed in a 1 L round-bottomed flask.
The reaction mixture is stirred at room temperature (25° C.) for 24 hours, followed by successive addition of 80 ml of aqueous hydrogen peroxide solution and 0.32 g of manganese dioxide.
The mixture is stirred for 1 hour 30 minutes and the phases are then separated by settling.
The aqueous phase is extracted with dichloromethane (2*200 ml).
The organic phases are combined, dried over sodium sulfate, filtered and concentrated under vacuum to give 64 g of 8-hydroxyquinoline N-oxide in the form of an orange-colored solid; m.p.=112° C. (Yield: 97percent)
97% With manganese dioxide; dihydrogen peroxide In dichloromethane (1)
8-Hydroxyquinoline N-Oxide
59.74 g (411 mmol) of 8-hydroxyquinoline, 350 ml (822 mmol) of dichloromethane, 82.2 ml of 35percent aqueous hydrogen peroxide solution and 0.52 g (2.5 mmol) of methylrhenium trioxide (MTO) are placed in a 1 l round-bottomed flask.
The reaction mixture is stirred at ambient temperature (25° C.) for 24 h and then 80 ml of aqueous hydrogen peroxide solution and 0.32 g of manganese dioxide are successively added.
The mixture is stirred for 1 h 30 and then separated by settling.
The aqueous phase is extracted with dichloromethane (2*200 ml).
The organic phases are combined, dried over sodium sulfate, filtered and concentrated under vacuum to provide 64 g of 8-hydroxyquinoline N-oxide in the form of an organe-colored solid; M.p.=112° C. (Yield: 97percent)
95% With dihydrogen peroxide; bis(triphenyl)oxodiphosphonium trifluoromethanesulfonate salt In ethanol at 20℃; for 0.833333 h; General procedure: In a 25-mL flask to a solution of Hendrickson reagent (1 mmol, 0.839 g) in 3 mL of ethanol at room temperature, H2O2 (4 mmol, 0.4 mL) was added, and the mixture allowed stirring for 15 min. Then, pyridine (1 mmol, 0.16 mL) was added to the mixture, and the solution was stirred again for appropriate time (Table 2). Upon completion of the reaction, the solvent was removed under reduced pressure, and then the saturated sodium bicarbonate solution (10 mL) was added. The product was extracted with chloroform (3 × 5 mL), washed with water, and dried over anhydrous MgSO4. The filtrate was evaporated and the crude product was purified by silica gel column chromatography using ethyl acetate/n-hexane (3:7) as eluent to afford pyridine-N-oxide (0.076 g, 80percent).
89% With dihydrogen peroxide In water for 0.416667 h; Sonication In a 50 mL round-bottomed flask, 1.45 g of 8-hydroxyquinoline, followed by hydrogen peroxide (35percent by mass), 1.1 g, 5percent were added.Mass fraction of perfluorosulfonic acid resin, 10 ml of water as a solvent, and the resulting mixture at 30 W/20 KHz in an ultrasonic reactor25 minutes under acoustic conditions. The perfluorosulfonic acid resin catalyst in the reaction system is removed by filtration, and the reaction solvent is removed under reduced pressureThe water was finally recrystallized to obtain a 1.63 g 6-chloroquinoline nitrogen oxide compound in 89percent yield.
76% With peracetic acid; acetic acid In dichloromethane; water at 0 - 20℃; for 5 h; To a solution of 8-hydroxyquinoline (50.0 g, 344 mmol) in methylene chloride (325 mL) was added dropwise at 0° C. dilute peroxyacetic acid (Fluka, 39percent in aqueous acetic acid, 75.1 mL, 440 mol), wherein the yellow solution became deep red. After warming and stirring at room temperature for 5 h, a solution of sodium disulfite (14.0 g, 74 mmol) in water (20 mL) was added dropwise. Here the solution turned dark yellow to black. The organic phase was washed successively with 1M hydrochloric acid (ca. 300 mL), sat. sodium hydrogen carbonate solution (ca. 200 mL), sat. potassium carbonate solution (ca. 150 mL) and sat. sodium chloride solution (ca. 200 mL). The yellow-brown solution was treated with silica gel (silica gel 60 for column chromatography, 0.063-0.200 mm, 5 g) and dried with sodium sulfate. After stirring at room temperature for 15 min, the solid was separated off and the solvent was removed on a rotary evaporator. A yellow to light-brownish solid was obtained, which was dried under fine vacuum. [0094] Yield: 42.4 g (263 mmol, 76percent), yellow solid. [0095] HR-ESI/MS (CH3OH): m/z calculated for [C9H7NO2+H]+: 162.0550. found: 162.0553; m/z calculated for [C9H7NO2+Na]+: 184.0374. found: 184.0374. [0096] 1H-NMR (300.1 MHz, CDCl3): δ (ppm)=7.09 (dd, J=7.9, 1.1 Hz, 1H, H7), 7.24-7.29 (m, 2H, H3/H5), 7.51 (t, J=7.9 Hz, 1H, H6), 7.81 (dd, J=8.5, 0.6 Hz, 1H, H4), 8.26 (dd, J=6.1, 1.0 Hz, 1H, H2), 15.09 (s, 1H, OH). [0097] 13C{1H}-NMR (75.5 MHz, CDCl3): δ (ppm)=114.6 (C7), 116.6 (C5), 120.3 (C3), 129.4 (C4), 129.7 (C4a), 130.3 (C6), 132.1 (C8a), 134.3 (C2), 153.8 (C8). [0098] CHN analysis: calculated for C9H7NO2 (161.16 g/mol): C, 67.07; H, 4.38; N, 8.69 wt percent. found: C, 67.14; H, 4.19; N, 8.63 wt percent.
76% With peracetic acid In dichloromethane; water at 0 - 20℃; for 5.25 h; To a solution of 8-hydroxyquinoline (50.0 g, 344 mmol) in methylene chloride (325 mL) were diluted peroxyacetic acid (Fluka, ~ 39percent in aqueous acetic acid, 75.1 mL, 440 mol) was added dropwise at 0 ° C, the yellow solution turned deep red.After heating and stirring at room temperature for 5 h, a solution of sodium (14.0 g, 74 mmol) in water (20 mL) was added dropwise.In this case, the solution turned dark yellow to black.The organic phase was washed successively with 1 M hydrochloric acid (300 mL), sat.Sodium bicarbonate solution (200 mL), sat.Potassium carbonate solution (150 mL) and sat.Sodium chloride solution.(Ca. 200 mL).The yellow-brown solution was treated with silica gel (silica gel 60 for column chromatography, 0.063-0.200 mm, 5g) and drying with sodium sulfate.After stirring at room temperature for 15 min, the solid was separated and the solvent removed on a rotary evaporator.This gave a yellow to light tan solid which was dried under vacuum fine. Yield: 42.4 g (263 mmol, 76percent), yellow solid.
70.3% With 3-chloro-benzenecarboperoxoic acid In dichloromethane at 20℃; Cooling with ice 0.5 g 8-hydroxyquinolinewas dissolved in 4 mL dichloromethane and 0.69 g metachloroperbenzoicacid (m-CPBA) was added stepwise in anice-cooled water bath. The resulting mixture was stirred atroom temperature overnight. 7.14 mL 2 M NaOH wasadded slowly to the above solution. The organic layer wasseparated and the water phase was washed with dichloromethane.The organic fractions were combined andwashed with brine, dried with sodium sulfate, and thenfiltered. The organic solvent was removed under reducedpressure, resulting in 0.39 g title compound as yellow solid(yield, 70.3 percent) 1H NMR (300 MHz, CDCl3) d 8.25 (dd,J = 6.0, 0.8 Hz, 1H), 7.80 (d, J = 8.1 Hz, 1H), 7.50 (t,J = 8.0 Hz, 1H), 7.25–7.21 (m, 2H), 7.08 (dd, 1H).
40% at 70℃; for 16 h; A solution of quinolin-8-ol (4 g, 27.6 mmol) in 35percent hydrogen peroxide solution (10 ml) in acetic acid (25 mL) was stirred at 70 °C for 16 hours. After the reaction mixture was neutralized to pH 12 with ammonium hydroxide, it was extracted with ethyl acetate (50 mL x 3). The organic layers were combined, dried over sodium sulfate and concentrated to dryness to afford 5-2 (1.8 g, 40percent yield) as a brown solid. MS (ESI): m/z 238 [M+H]+.

Reference: [1] Naunyn-Schmiedeberg's Archives of Pharmacology, 1999, vol. 359, # 3, p. 168 - 177
[2] ChemCatChem, 2015, vol. 7, # 23, p. 3903 - 3910
[3] Patent: US2003/97000, 2003, A1,
[4] Patent: US6617336, 2003, B1,
[5] Organic Letters, 2011, vol. 13, # 14, p. 3556 - 3559
[6] European Journal of Inorganic Chemistry, 2016, vol. 2016, # 35, p. 5449 - 5455
[7] Journal of the Iranian Chemical Society, 2018, vol. 15, # 8, p. 1843 - 1849
[8] Advanced Synthesis and Catalysis, 2004, vol. 346, # 2-3, p. 339 - 345
[9] Advanced Synthesis and Catalysis, 2005, vol. 347, # 15, p. 1958 - 1960
[10] Organic and Biomolecular Chemistry, 2014, vol. 12, # 19, p. 3026 - 3036
[11] RSC Advances, 2015, vol. 5, # 46, p. 36809 - 36812
[12] Patent: CN108003098, 2018, A, . Location in patent: Paragraph 0082; 0083; 0084
[13] Synthetic Communications, 2001, vol. 31, # 2, p. 167 - 172
[14] Organic Process Research and Development, 2004, vol. 8, # 4, p. 663 - 665
[15] New Journal of Chemistry, 2013, vol. 37, # 9, p. 2614 - 2618
[16] Tetrahedron Letters, 1988, vol. 29, # 12, p. 1351 - 1354
[17] Patent: US2015/203467, 2015, A1, . Location in patent: Paragraph 0093-0098
[18] Patent: KR2015/44896, 2015, A, . Location in patent: Paragraph 0124-0127
[19] Organic Letters, 2003, vol. 5, # 21, p. 3787 - 3790
[20] Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry, 1984, vol. 23, # 6, p. 496 - 497
[21] Journal of Biomolecular NMR, 2016, vol. 64, # 2, p. 103 - 113
[22] Chemistry - A European Journal, 2005, vol. 11, # 23, p. 6818 - 6828
[23] Science China Chemistry, 2010, vol. 53, # 6, p. 1294 - 1301
[24] Patent: WO2013/169964, 2013, A1, . Location in patent: Paragraph 00265; 00266
[25] Journal of Chemical Sciences, 2010, vol. 122, # 6, p. 847 - 855
[26] Canadian Journal of Chemistry, 2005, vol. 83, # 5, p. 460 - 470
[27] Chemistry of Heterocyclic Compounds (New York, NY, United States), 1981, vol. 17, # 1, p. 72 - 76[28] Khimiya Geterotsiklicheskikh Soedinenii, 1981, # 1, p. 89 - 94
[29] Zhurnal Obshchei Khimii, 1958, vol. 28, p. 2355,2358; engl. Ausg. S. 2393, 2395
[30] Nippon Kagaku Zasshi, 1954, vol. 75, p. 1180,1181[31] Chem.Abstr., 1955, p. 10785
[32] Tetrahedron, 1986, vol. 42, # 18, p. 5065 - 5071
[33] Synlett, 2006, # 6, p. 924 - 926
[34] Journal of the American Chemical Society, 2009, vol. 131, # 39, p. 13888 - 13889
[35] Journal of Molecular Catalysis A: Chemical, 2011, vol. 337, # 1-2, p. 45 - 51
[36] Journal of Organic Chemistry, 2011, vol. 76, # 9, p. 3151 - 3159
[37] Patent: US2012/46467, 2012, A1, . Location in patent: Page/Page column 19
[38] European Journal of Organic Chemistry, 2016, vol. 2016, # 8, p. 1606 - 1611
[39] Organic Letters, 2016, vol. 18, # 8, p. 1796 - 1799
[40] Green Chemistry, 2016, vol. 18, # 12, p. 3518 - 3521
[41] Organic Letters, 2016, vol. 18, # 10, p. 2495 - 2498
[42] RSC Advances, 2016, vol. 6, # 63, p. 58118 - 58124
[43] Bioorganic and Medicinal Chemistry, 2016, vol. 24, # 19, p. 4741 - 4749
[44] Chemical Communications, 2001, # 5, p. 487 - 488
[45] Bioorganic and Medicinal Chemistry, 2017, vol. 25, # 20, p. 5576 - 5585
[46] Advanced Synthesis and Catalysis, 2018, vol. 360, # 5, p. 905 - 910
  • 4
  • [ 148-24-3 ]
  • [ 1127-45-3 ]
Reference: [1] Patent: US5646164, 1997, A,
  • 5
  • [ 148-24-3 ]
  • [ 64741-01-1 ]
  • [ 1127-45-3 ]
Reference: [1] Patent: US5021567, 1991, A,
  • 6
  • [ 79-21-0 ]
  • [ 148-24-3 ]
  • [ 1127-45-3 ]
Reference: [1] Trans. Kentucky Acad., 1956, vol. 17, p. 135,137
[2] Zhurnal Obshchei Khimii, 1958, vol. 28, p. 2355,2358; engl. Ausg. S. 2393, 2395
  • 7
  • [ 148-24-3 ]
  • [ 2311-91-3 ]
  • [ 1127-45-3 ]
Reference: [1] Nippon Kagaku Zasshi, 1954, vol. 75, p. 1180,1181[2] Chem.Abstr., 1955, p. 10785
[3] Journal of the Chemical Society, 1954, p. 570,572
  • 8
  • [ 148-24-3 ]
  • [ 93-59-4 ]
  • [ 1127-45-3 ]
Reference: [1] Zhurnal Obshchei Khimii, 1958, vol. 28, p. 2355,2358; engl. Ausg. S. 2393, 2395
[2] Zhurnal Obshchei Khimii, 1952, vol. 22, p. 1224,1226; engl. Ausg. S. 1269, 1[3] Engl. Ausg. S. 1269, 1270,
  • 9
  • [ 1127-45-3 ]
  • [ 31568-91-9 ]
Reference: [1] European Journal of Organic Chemistry, 2016, vol. 2016, # 8, p. 1606 - 1611
[2] Canadian Journal of Chemistry, 2005, vol. 83, # 5, p. 460 - 470
[3] Journal of Fluorescence, 2018, vol. 28, # 5, p. 1121 - 1126
  • 10
  • [ 1127-45-3 ]
  • [ 93609-84-8 ]
Reference: [1] Patent: US2012/46467, 2012, A1,
  • 11
  • [ 1127-45-3 ]
  • [ 343788-51-2 ]
Reference: [1] Bioorganic and Medicinal Chemistry, 2017, vol. 25, # 20, p. 5576 - 5585
  • 12
  • [ 1127-45-3 ]
  • [ 530084-79-8 ]
Reference: [1] Patent: US2012/46467, 2012, A1,
  • 13
  • [ 1127-45-3 ]
  • [ 100331-89-3 ]
Reference: [1] Patent: US2012/46467, 2012, A1,
Same Skeleton Products
Historical Records

Related Parent Nucleus of
[ 1127-45-3 ]

Quinolines

Chemical Structure| 580-16-5

[ 580-16-5 ]

6-Hydroxyquinoline

Similarity: 0.68

Chemical Structure| 100516-88-9

[ 100516-88-9 ]

Quinolin-6-ylmethanol

Similarity: 0.63

Chemical Structure| 580-18-7

[ 580-18-7 ]

3-Hydroxyquinoline

Similarity: 0.61

Chemical Structure| 613-50-3

[ 613-50-3 ]

6-Nitroquinoline

Similarity: 0.56

Chemical Structure| 4113-04-6

[ 4113-04-6 ]

6-Quinolinecarboxaldehyde

Similarity: 0.55